SUTRO BIOPHARMA, INC.

Sutro Biopharma develops oncology therapeutics using proprietary platforms for antibody drug conjugate (ADC) discovery and manufacturing. The company's XpressCF cell-free protein synthesis platform and XpressCF+ site-specific conjugation platform enable the design of ADCs targeting various cancer types. STRO-004, the lead candidate, targets tissue factor in solid tumors including cervical, lung, and breast cancers. STRO-003 targets ROR1 and is in development for triple negative breast cancer, non-small cell lung cancer, ovarian cancer, and hematological malignancies.

Beyond oncology, Sutro pursues vaccine development through a partnership with Vaxcyte, with VAX-24 and VAX-31 pneumococcal conjugate vaccine candidates in Phase II/III trials for invasive pneumococcal disease. The company has established collaboration and licensing agreements with multiple pharmaceutical partners, including Ipsen for STRO-003 development, Tasly Biopharmaceuticals for STRO-002 commercialization in Greater China, and Astellas Pharma for immunostimulatory ADC development.

Based in South San Francisco, California, Sutro Biopharma operates with approximately 178 full-time employees and maintains a market capitalization of $0.3 billion. The company was incorporated in 2003 and is publicly traded on Nasdaq.